Hospital Nossa Senhora da Conceição-Porto Alegre-Brazil, Porto Alegre-RS Brazil.
Ann Hepatol. 2010 Apr-Jun;9(2):150-5.
The most important factors to predict the sustained virological response (SVR) are the genotype and the fibrosis grade, although there are other predictive factors to be considered, mainly in HCV/HIV coinfected patients.
To evaluate different prognostic factors to obtain the SVR in HCV monoinfected and HCV/HIV coinfected genotype 1 patients emphasizing the type of early virological response (EVR)-complete or partial.
This is a cohort study, retrospective, where the registers of HCV monoinfected or HCV/HIV coinfected patients, genotype 1, treated with pegylated interferon + ribavirin were reviewed. The prognostic factors: age greater than 40 years, viral load higher than 600,000UI/mL, and fibrosis grade (score METAVIR) were evaluated pre-treatment, and also the EVR considering the reduction of 100 times of the basal viral load (partial EVR) or negative PCR (complete EVR) in the week 12. In the statistical analysis, multivariate analysis was used. The significance level adopted was 5%.
There were 323 HCV monoinfected and 59 HCV/HIV coinfected. The SVR was 35.3% in monoinfected and 23% in coinfected patients. The worst results was observed in those with age greater than 40 years, high viral load, pronounced fibrosis (F4) and partial EVR, with an expected probability of 1.9% for SVR in those coinfected and 3.8% in monoinfected. In conclusion, patients with cirrhosis HCV genotype 1, age greater than 40 years, high viral load, coinfected with HIV or not, will present a low SVR if did not obtain negative PCR in week 12, and should be evaluated for discontinuation.
预测持续病毒学应答(SVR)的最重要因素是基因型和纤维化程度,尽管还有其他预测因素需要考虑,主要是在 HCV/HIV 合并感染患者中。
评估不同的预测因素,以获得 HCV 单感染和 HCV/HIV 合并感染基因型 1 患者的 SVR,重点是完全或部分早期病毒学应答(EVR)的类型。
这是一项回顾性队列研究,对接受聚乙二醇干扰素+利巴韦林治疗的 HCV 单感染或 HCV/HIV 合并感染基因型 1 患者的登记册进行了审查。在治疗前评估了预测因素:年龄大于 40 岁、病毒载量大于 600,000UI/mL 和纤维化程度(METAVIR 评分),还评估了在第 12 周时降低 100 倍基础病毒载量(部分 EVR)或 PCR 阴性(完全 EVR)的 EVR。在统计分析中,使用了多变量分析。采用的显著性水平为 5%。
共有 323 例 HCV 单感染和 59 例 HCV/HIV 合并感染患者。单感染患者的 SVR 为 35.3%,合并感染患者的 SVR 为 23%。在年龄大于 40 岁、高病毒载量、明显纤维化(F4)和部分 EVR 的患者中观察到最差的结果,合并感染患者的 SVR 预期概率为 1.9%,单感染患者的 SVR 预期概率为 3.8%。总之,基因型 1 HCV 肝硬化、年龄大于 40 岁、高病毒载量、合并或不合并 HIV 感染的患者,如果在第 12 周未获得阴性 PCR,SVR 较低,应评估是否停药。